Quick Answer
Fortress Biotech, Inc. reported Cash and Equivalents of $79.38 million for fiscal year 2025.
Fortress Biotech, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $79.38M | +38.6% |
| 2024 | $57.26M | -29.2% |
| 2023 | $80.93M | -54.6% |
| 2022 | $178.27M | -41.7% |
| 2021 | $305.74M | +31.0% |
| 2020 | $233.35M | +70.5% |
| 2019 | $136.86M | +108.9% |
| 2018 | $65.51M | -31.0% |
| 2017 | $94.95M | +7.5% |
| 2016 | $88.29M | -10.1% |
| 2015 | $98.18M | +97.3% |
| 2014 | $49.76M | -50.0% |
| 2013 | $99.52M | +147.6% |
| 2012 | $40.20M | +73.6% |
| 2011 | $23.16M | +55.8% |
| 2010 | $14.86M | +884.2% |
| 2009 | $1.51M | +21471.4% |
| 2008 | $7.0K | — |
| 2006 | $0.00 | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $86.22M | +46.5% | +15.9% |
| June 30, 2025 | $74.39M | -2.4% | -18.6% |
| March 31, 2025 | $91.34M | +9.0% | +59.5% |
| December 31, 2024 | $57.26M | -29.2% | -2.7% |
| September 30, 2024 | $58.85M | -18.6% | -22.8% |
| June 30, 2024 | $76.20M | -2.3% | -9.0% |
| March 31, 2024 | $83.77M | -45.1% | +3.5% |
| December 31, 2023 | $80.93M | -54.6% | +11.9% |
- Fortress Biotech, Inc. showed an increase of +38.6% in Cash and Equivalents compared to the prior fiscal year.
- The most recent figure is from Fortress Biotech, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: